

1 **TITLE: Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 -**

2 **The Vall d’Hebron COVID-19 prospective cohort study.**

3 **TITLE: Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 -**

4 **The Vall d’Hebron COVID-19 prospective cohort study.**

5

6 **Adrián Sánchez-Montalvá, MD, PhD,^{1,8,9} Júlia Sellarés-Nadal, MD,¹ Juan Espinosa-**

7 **Pereiro, MD,^{1,8} Nuria Fernández-Hidalgo, MD, PhD,^{1,10} Santiago Pérez-Hoyos, PhD,²**

8 **Fernando Salvador, MD, PhD,^{1,8,9} Xavier Durà, MD,¹ Marta Miarons, Pharm D,**

9 **PhD,³ Andrés Antón, PhD,^{4,10} Simeón Eremiev-Eremiev, MD,¹ Abiu Sempere-**

10 **González, MD,¹ Arnau Monforte-Pallarés, MD,¹ Pau Bosch-Nicolau, MD,¹ Salvador**

11 **Augustin, MD, PhD,⁵ Júlia Sampol, MD,⁶ Alfredo Guillén-del-Castillo, MD, PhD,⁷**

12 **Benito Almirante MD, PhD.^{1,10}**

13 ¹Infectious Diseases Department, Vall d’Hebron University Hospital, Universitat

14 Autònoma de Barcelona, Barcelona, Spain;

15 ²Statistic Unit, Vall d’Hebron Institute of Research, Barcelona, Spain;

16 ³Pharmacy Department, Vall d’Hebron University Hospital, Universitat Autònoma de

17 Barcelona, Barcelona, Spain;

18 ⁴Microbiology Department, Vall d’Hebron University Hospital, Universitat Autònoma de

19 Barcelona, Barcelona, Spain;

20 ⁵Hepatology Department, Vall d’Hebron University Hospital, Universitat Autònoma de

21 Barcelona, Barcelona, Spain;

22 ⁶Pneumology Department, Vall d’Hebron University Hospital, Universitat Autònoma de

23 Barcelona, Barcelona, Spain;

24 ⁷Internal Medicine Department, Vall d'Hebron University Hospital, Universitat Autònoma
25 de Barcelona, Barcelona, Spain;

26 ⁸International Health Program of the Catalan Institut of Health (PROSICS), Barcelona,
27 Spain;

28 ⁹Tropical Medicine Spanish Research Network (RICET), Madrid, Spain;

29 ¹⁰Infectious Diseases Spanish Research Network (REIPI), Madrid, Spain;

30

31 **Address correspondence to:**

32 Adrián Sánchez-Montalvá, MD, PhD (corresponding author)

33 Address: Passeig Vall d'Hebron, 119-129. Hospital Universitario Vall d'Hebron. Edificio
34 General. Enfermedades Infecciosas. 6^a planta. CP 08035. Barcelona. Spain.

35 e-mail: adsanche@vhebron.net . Telephone number: +34 93 274 6090 Fax number: +34 93
36 489 40 91.

37 **Running title:** Tocilizumab in COVID19

38 **Word count (abstract):** 249

39 **Word count:** 3742

40 **Tables:** 7

41 **Figures:** 4

42 **Sources of funding:** none.

43 **Summary of the article's main point:** In patient with COVID-19 and lung injury, time
44 from lung injury onset to tocilizumab administration may be critical to patient recovery.
45 Early administration of host-directed therapies may improve patient outcome.

46 **ABSTRACT**

47 **Background:** Modulation of the immune system to prevent lung injury is being widely
48 used against the new coronavirus disease (COVID-19) despite the scarcity of evidence.

49 **Methods:** We report the preliminary results from the Vall d’Hebron prospective cohort
50 study at Vall d’Hebron University Hospital, in Barcelona (Spain), including all consecutive
51 patients who had a confirmed infection with the severe acute respiratory syndrome
52 coronavirus-2 (SARS-CoV-2) and who were treated with tocilizumab until March 25th. The
53 primary endpoint was mortality at 7 days after tocilizumab administration. Secondary
54 endpoints were admission to the intensive care unit, development of ARDS and respiratory
55 insufficiency among others.

56 **Results:** 82 patients with COVID-19 received at least one dose of tocilizumab. The mean
57 (\pm SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and
58 the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory
59 failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median
60 time from symptom onset to ARDS development was 8 (5-11) days. The median time from
61 symptom onset to the first dose of tocilizumab was 9 (7-11) days. Mortality at 7 days was
62 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 (age-adjusted hazard ratio for
63 mortality 2.1; 95% CI, 0.8 to 5.8) if tocilizumab was administered after the onset of ARDS.

64 **Conclusion:** Time from lung injury onset to tocilizumab administration may be critical to
65 patient recovery. Our preliminary data could inform bedside decisions until more data from
66 clinical trials becomes available.

67

68

69 **INTRODUCTION:**

70 Coronavirus disease 2019 (COVID-19) is a novel illness caused by severe acute respiratory
71 syndrome coronavirus-2 (SARS-CoV-2). It was first reported in December 2019 in Hubei
72 province, China.¹ Since then, SARS-CoV-2 has rapidly spread worldwide.
73 According to the World Health Organization (WHO), as of July 8th, 2020, there have been
74 11.669.259 laboratory-confirmed cases and 539.906 deaths.² The crude case fatality rate,
75 estimated to be between 2.3% and 3.3%, is highly dependent on age and underlying
76 conditions.^{3,4} Death is mainly due to respiratory failure caused by an acute respiratory
77 distress syndrome (ARDS). As the pathophysiology behind lung injury is progressively
78 elucidated, several therapies have been proposed on the basis of pre-clinical studies and the
79 previous experience with the severe acute respiratory syndrome coronavirus (SARS-CoV)
80 and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).^{5,6} Many of them
81 are being used off-label in a desperate attempt to improve patient outcomes, including
82 antiviral therapies, coagulation-modifying drugs and immune-modulating therapies.⁷⁻¹¹
83 In COVID-19, an excessive immune response inducing disproportionate release of
84 cytokines and hyperinflammation has been proposed as a cause for the lung damage,
85 mimicking a secondary haemophagocytic lymphohistiocytosis.¹² Host-directed therapies
86 have immune-modulating properties with higher precision than steroids and other immune-
87 modulating therapies.¹³ Tocilizumab is a humanized monoclonal antibody that inhibits
88 interleukin-6 (IL-6) receptor with a well-known safety profile and is approved for the
89 treatment of rheumatoid arthritis and, since 2017, the treatment of chimeric antigen receptor
90 (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS).^{14,15} It
91 has been used with promising results in small retrospective cohort studies of SARS-CoV-2
92 infected patients in China.^{9,16} The efficacy of other host-directed therapies targeting

93 hyperinflammation is being assessed under randomized clinical trial conditions for severe
94 SARS-CoV-2 infected patients.^{17,18}
95 However, a proper characterization of the subset of patients who will benefit most from
96 host-directed therapy and defining the precise timing for host-directed therapies
97 administration has not yet been performed and is critical to allocate limited drug stocks and
98 reduce COVID-19 associated mortality. We aim to describe a prospective cohort of SARS-
99 CoV-2 infected patients treated with tocilizumab and define risk factors associated with
100 poor outcome.

101 **METHODS**

102 **Study setting and population**

103 The Vall d’Hebron COVID-19 Prospective Cohort Study includes all consecutive adult
104 patients (≥ 18 years old) treated for COVID-19 at Vall d’Hebron University Hospital, a
105 1100-bed public tertiary care hospital in Barcelona, Spain. For this study we selected the
106 subgroup of patients with laboratory-confirmed COVID-19 and radiologically confirmed
107 pneumonia who received at least one dose of tocilizumab. Identification and inclusion of
108 patients receiving tocilizumab was performed from the Pharmacy Department registry.

109 **Standard of care and tocilizumab administration criteria**

110 At admission, all patients were initially evaluated with chest radiography and blood tests
111 including complete cell count, coagulation studies, biochemistry and inflammatory
112 parameters. Treatment with lopinavir/ritonavir, azithromycin and hydroxychloroquine was
113 initiated according to Vall d’Hebron University Hospital protocol. Tocilizumab was
114 considered as additional treatment in patients with the following criteria: 1) respiratory
115 failure defined as a ratio of arterial oxygen tension to fraction of inspired oxygen
116 ($\text{PaO}_2/\text{FiO}_2$ ratio) of <300 , a ratio of arterial oxygen saturation measured by pulse
117 oximetry to fraction of inspired oxygen ($\text{SpO}_2/\text{FiO}_2$ ratio) of <315 or $\text{pO}_2 <60\text{mmHg}$ or
118 oxygen saturation measured by pulse oximetry less than 90% when breathing room air or
119 rapidly progressive clinical worsening according to treating physician and 2) interleukin-6
120 (IL-6) levels $>40\text{pg/mL}$ (reference 0-4.3 pg/mL) or a D-dimer levels $> 1500 \text{ ng/mL}$
121 (reference 0-243 pg/mL). Two dosing regimens based on weight were considered for
122 tocilizumab. Patients over 75kg received 600mg, otherwise 400mg was the preferred dose.
123 A second dose was considered in patients with a poor early response. Patients with liver
124 enzymes (aspartate aminotransferase and alanine aminotransferase) 5 times over the upper

125 limit of normality or concomitant severe bacterial infection were not eligible for
126 tocilizumab treatment.

127 **Data sources**

128 Data were collected retrospectively from the medical charts of patients from the 13th of
129 March, 2020 to the 18th of March, 2020, when the protocol was submitted to the
130 institutional review board, and prospectively thereafter. Inclusion and follow-up are still
131 ongoing. The cut-off data for inclusion in this sub-study was the 25th of March, 2020. All
132 patients included were followed for at least 7 days. The institutional review board provided
133 ethical clearance (local review board code number: PR(AG)183/2020). Patients were asked
134 for an oral consent. The institutional review board granted an informed consent waiver if
135 patients were unable to give oral consent. Written consent was waived because of the crisis
136 context and concerns about safety when introducing a physical support for the consent in
137 the isolation areas.

138 A Laboratory-confirmed case was defined as a patient with a real-time reverse-
139 transcriptase-polymerase-chain-reaction (RT-PCR) SARS-CoV-2 positive result in any
140 respiratory sample (nasopharyngeal swab, sputum, bronchoalveolar lavage or aspirate,
141 tracheal aspirate).

142 We collected sociodemographic characteristics, past medical history, Charlson comorbidity
143 score, concomitant medication, current therapy, adverse drug events, blood test results,
144 imaging studies, microbiological tests other than SARS-CoV-2 RT-PCR on respiratory
145 samples when available, and supportive measures needed. Vital signs, symptoms and
146 physical examination were evaluated on admission, at 48h and weekly during hospital
147 admission. Laboratory, microbiology and imaging studies were performed on admission
148 and thereafter according to the clinical care needs of each patient. Laboratory assessments

149 consisted of a complete blood count, coagulation testing including D-dimer measurement,
150 liver and renal tests, electrolyte profile, and inflammatory profile including C-reactive
151 protein, fibrinogen, ferritin and IL-6. All radiographs were reviewed by the investigators
152 and computed tomography (CT) scans were recorded according to the radiology department
153 reports. The COVID-19 severity was measured with the CURB-65 scale for community
154 acquired pneumonia and other scales.^{19,20} Data was recorded in the Research Electronic
155 Data Capture software (REDCap, Vanderbilt University).

156 **Laboratory confirmation**

157 From the onset of the outbreak until 15th of March the microbiological diagnosis was based
158 on a homebrew RT-PCR assay targeting two viral targets (N1 and N2) in the viral
159 nucleocapsid (N) gene and one in the envelope (E) gene of SARS-CoV-2, as well as the
160 human RNase P (RP) gene as an internal control of the whole process, according to the
161 CDC and ECDC Real-Time RT-PCR Diagnostic Panels with minor modifications.²¹ Since
162 March 15th, commercial Allplex™ 2019-nCoV multiplex RT-PCR (Seegene, South Korea)
163 were used for the detection of three viral targets (E; N; and, RNA-dependent RNA
164 polymerase, RdRp) and an internal control. First SARS-CoV-2 laboratory-confirmations
165 were confirmed by RdRp sequencing.^{22,23} Total nucleic acids (DNA/RNA) were extracted
166 from respiratory specimens using NucliSENS easyMAG (BioMerieux, France)
167 and STARMag Universal Cartridge Kit (Seegene, South Korea) according to the
168 manufacturer's instructions. All microbiological procedures were carried out in the
169 laboratory under Biosafety Level 2 conditions.

170 **Study outcomes**

171 The primary simple endpoint was defined as death at 7 days after first dose of tocilizumab.
172 Secondary outcomes were admission to Intensive Care Unit (ICU), acute Respiratory
173 Distress Syndrome (ARDS) and respiratory insufficiency. We also assessed acute
174 myocardial infarction, septic shock, acute kidney injury and secondary infections. Berlin
175 criteria for the ARDS were adapted, as many of the patients did not have an available
176 arterial O₂ pressure due to the overwhelming volume of admitted patients that precluded us
177 from performing arterial blood samples on all patients. Instead, we used oxygen saturation
178 by pulse oximetry and its correlation to the inspired fraction of oxygen (SpO₂/FiO₂ ratio <
179 315).^{24,25} One patient died a few hours after receiving tocilizumab and was excluded from
180 the primary endpoint analysis.

181 **Statistical analysis**

182 Continuous variables were expressed as mean and standard deviation or medians and
183 interquartile range, as appropriate. Categorical variables were summarized as absolute
184 number and percentages. Comparisons among groups was performed with Chi squared test
185 and Fisher's test for categorical variables; and Student's T test and Mann-Whitney U test
186 for continuous variables. Box plots and bar plots are also provided for some associations.
187 Mortality in the cohort was described with the use of Kaplan-Meier analysis. Tests were
188 considered significant when the two-tailed p-value was <0.05. We did not correct for
189 multiple comparisons; hence, the widths of the confidence intervals should not be
190 interpreted as definitive for the associations with the outcomes. Association between time
191 to tocilizumab administration and mortality were assessed by means of Cox proportional
192 hazards regression. Missing urea and bilirubin levels on admission were assumed normal
193 for CURB-65 and SOFA calculation; no other imputation was made for missing data.
194 Analysis was performed with Stata 15.1 software (StataCorp).

195

196 **Study oversight**

197 The study was designed and conducted by the investigators from the Vall d'Hebron
198 COVID-19 Prospective Cohort Study. No specific funding was provided to conduct the
199 study. Data were collected, debugged, analysed and interpreted by the authors. All the
200 authors reviewed the manuscript and vouch for the accuracy and completeness of the data
201 and for the adherence of the study to the protocol.

202

203 **RESULTS:**

204 **Demographic and clinical characteristics**

205 Since the onset of the COVID-19 outbreak until March 25th, 3242 respiratory-derived
206 samples have been requested from our institution for COVID-19 diagnosis. Samples were
207 requested from the emergency room and hospital wards, as well as from the health care
208 worker surveillance strategy plan. From them, 941 were positive (29%). During this period,
209 82 SARS-CoV-2 infected patients received at least one dose of tocilizumab. The mean
210 (\pm SD) age was 59.1 (\pm 19.8) years (95% Confidence Interval 54.8-63.5). Fifty-two patients
211 were male (63.5%). Eighteen (21.9%) patients were born abroad, 13 (16.1%) in Latin
212 America, 3 (3.7%) in Eastern Europe and 2 (2.4%) in North Africa. The mean (\pm SD)
213 duration of symptoms before hospital admission was 6.7 (\pm 4.4) days. Fever and cough were
214 the main symptoms on admission, occurring in 75 (91.5%) and 71 (86.6%) cases
215 respectively.

216 Thirty-three (40.3%) patients were former or active tobacco smokers. Coexisting conditions
217 were as follows: 32 (39.0%) had hypertension, 19 (23.5%) had lung diseases (2 (2.4%)
218 asthma, 6 (7.3%) chronic obstructive pulmonary disease among others), 17 (20.7%) had
219 obesity, 16 (19.5%) had diabetes mellitus, 11 (13.6%) had chronic kidney disease, 5 (6.1%)
220 a history of cardiac failure, 1 (1.2%) had cirrhosis. Ten (12.5%) patients were
221 immunosuppressed because of different conditions. Seventy-seven (95.1%) patients had a
222 Barthel scale index of 100 points previous to hospital admission. Table 1 shows
223 demographic and clinical characteristics at baseline.

224 **Laboratory and Radiologic findings**

225 On admission, mean (\pm SD) white cell count was 9.2 (10.4) with 17 (21.3%) patients having
226 more than 10000 per cubic millilitre white cells. Lymphocytopenia (<1000 cells per cubic

227 millilitre) was present in 46 (57.5%) patients. Interleukin-6 median (IQR) plasma level on
228 admission was 74.8 (49.4-120.0) ng/ml. Liver enzymes were below five times the upper
229 normal value in all patients. Pneumonia was radiologically proven in all patients on
230 admission or during follow up. Tables 2 and 3 describe laboratory and radiologic findings
231 on admission and during follow up.

232 **Microbiologic results**

233 All included patients had a positive RT-PCR for SARS-CoV-2 in a respiratory-derived
234 sample. On admission, 2 patients out of 56 had a positive pneumococcal urinary antigen
235 result. Sputum samples from 13 patients were sent on admission, bacterial growth was
236 demonstrated in 3 samples, two with *Haemophilus influenzae* that were considered
237 clinically significant and one was deemed contamination with oral bacteria. During the first
238 7 days follow up, 2 more positive results were retrieved: one Extended-Spectrum Beta-
239 Lactamase (ESBL)-producing *Escherichia coli* (considered clinically significant) and one
240 *Staphylococcus epidermidis* (considered non-clinically significant). Blood cultures from 65
241 patients were sent, and one positive bacterial growth (coagulase-negative *Staphylococcus*)
242 was observed, although considered a contamination. Detailed microbiologic data are shown
243 in Table 3.

244 **Oxygen supplementation and secondary outcomes.**

245 Table 4 shows oxygen saturation, oxygen supplementation and ventilation support. On
246 admission, mean FiO₂ oxygen supplementation was 0.36 (\pm 0.26) and mean oxygen
247 saturation was 94% (\pm 4.39). Regarding oxygen supplementation devices on admission, 34
248 (41.5%) patients were on oxygen supplementation: two (5.8%) patients were on nasal
249 cannulas, 22 (64.7%) were using face masks, 9 (26.5%) patients were using high oxygen
250 supplementation devices and 1 (2.9%) patient required endotracheal intubation with

251 mechanical ventilation. Over time, SpO₂/FiO₂ ratio deteriorated from a median (IQR) of
252 428 (316.1-454.8) on admission, 271.4 (158.3-361.5) at 48 hours and 230.2 (118.8-346.4)
253 at 7 days follow up (p<0.001). Fifty-five (69.6%) patients required intensive oxygen
254 therapy, including high flow oxygen delivery systems, high flow nasal cannula, non-
255 invasive mechanical ventilation or invasive ventilation during the study period. Median
256 (IQR) days on high flow oxygen delivery systems, high flow nasal cannula, non-invasive
257 mechanical ventilation or invasive ventilation before progression to other intensive oxygen
258 therapy, outcome attainment or data censoring were 2.0 (1.0-3.0), 4.0 (2.0-6.0), 3.0 (2.0-
259 4.0) and 9.0 (9.0-9.0) respectively. The median (IQR) days from admission to first intensive
260 oxygen therapy was 2.0 (1.0-4.5). Only one (1.2%) patient required vasopressor therapy
261 due to hypotension. No patient required renal replacement therapy. Respiratory failure and
262 ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median (IQR) days
263 from symptoms to respiratory failure and ARDS were 8 (6.0-11.0) and 8 (5.0-11.0)
264 respectively. Median (IQR) days from admission to respiratory failure and ARDS were 1
265 (0.0-3.0) and 2 (1.0-4.0) respectively. Secondary outcomes can be found in Table 5.

266 **Tocilizumab treatment and concomitant treatment**

267 Eighty-one (98.9%) patients received hydroxychloroquine, 63 (76.8%) lopinavir/ritonavir,
268 21 (25.61%) darunavir/cobicistat, and 79 (96.34%) azithromycin. All patients were initially
269 treated with antibiotic therapy, mainly ceftriaxone (77 (93.9%) patients). As expressed
270 before, all patients received at least one dose of tocilizumab. Median (IQR) time in days
271 from symptom onset to tocilizumab administration was 9.0 (6.0-11.0) and from admission
272 to tocilizumab administration was 2.0 (1.0-3.0)). Other treatments include cytokine
273 hemoadsorption therapy in 2 (2.4%) patients in ICU.

274 **Primary outcome and mortality risk factors**

275 Table 6 summarizes primary outcome in the study population. At the end of the follow up
276 period, of the 82 patients 34 (41.5%) had been discharged, 22 (26.8%) had died, 14 (17.1%)
277 were hospitalized in ICU, 9 (11.0%) were hospitalized in medical wards, and 3 (3.7%) had
278 been transferred to another institution. In the univariate analysis age, age-adjusted Charlson
279 comorbidity index, medical history of active or former solid cancer, hypertension, history
280 of heart failure, chronic kidney disease and worse age-adjusted Charlson index at baseline
281 were associated with increased risk of mortality (Table 7). By 7-day follow-up, the
282 mortality rate was 4.0% per person-day (95% confidence interval [CI], 2.4% to 6.2%) by
283 Kaplan-Meier analysis. Mortality was more frequent in patients receiving tocilizumab once
284 ARDS was present (hazard ratio for mortality 3.3; 95% CI, 1.3 to 8.5; age-adjusted hazard
285 ratio for mortality 2.1; 95% CI, 0.8 to 5.8)(Figure 1) or respiratory failure was present
286 (hazard ratio for mortality 3.13; 95% CI, 1.3 to 7.8; age-adjusted hazard ratio for mortality
287 2.4; 95% CI, 0.9 to 6.4)(Figure 2). When dividing patients according to the nearest
288 SpO₂/FiO₂ ratio to tocilizumab administration, mortality was higher among patients with
289 lower SpO₂/FiO₂ ratio (SpO₂/FiO₂ ratio<200, 46.2%; SpO₂/FiO₂ ratio 200-300, 16.7%;
290 SpO₂/FiO₂ ratio >300, 20.6%; p=0.03)(Figure 3). Distribution of the nearest SpO₂/FiO₂
291 ratio to tocilizumab administration depending on outcome groups was not statistically
292 significant (mean (SD) SpO₂/FiO₂ ratio: 321.3 (154.7) dead, 343.1 (132.7) ICU, 396.9
293 (96.2) alive; p=0.2)(Figure 4). No correlation was observed between nearest IL-6 levels to
294 tocilizumab administration and main outcome (median (IQR) IL-6 levels: 79.7 (48.2-128.1)
295 dead, 77.5 (55-120) ICU admission, 71.4 (49.4-116) alive; p=0.92). Basal characteristics of
296 patients stratified by ARDS and respiratory failure can be found in the Supplementary
297 Appendix.

298 **Safety**

299
300 Twelve (14.63%) out of 82 patients reported a total of 14 adverse events during the follow
301 up. Thirteen (92.9%) adverse events were considered related to lopinavir/ritonavir, 9
302 (75.0%) patients discontinued lopinavir/ritonavir treatment due to gastrointestinal
303 symptoms. Diarrhoea was the most common reported adverse event. Other adverse events
304 included nausea and dysuria. There were no adverse events attributed to tocilizumab. No
305 serious adverse events were reported during follow up, and only 2 (14.3%) were considered
306 moderate. Eleven (91.7%) patients recovered without medical sequelae and one patient had
307 an unknown outcome. No tocilizumab discontinuation was reported due to adverse events.
308

309 **DISCUSSION**

310 This preliminary report from the Vall d'Hebron COVID-19 Prospective Cohort Study
311 describes the characteristics and clinical outcomes of patients who were hospitalized in
312 non-ICU wards and received treatment with tocilizumab. Our results show that a timely
313 administration of immune-modulating therapies, before the onset of respiratory
314 insufficiency or ARDS, may improve severe COVID-19 patients' outcomes.
315 Therapies to improve outcomes of patients with COVID-19 focus on viral-directed
316 therapies and host-directed therapies. There is still lack of evidence about the efficacy of
317 any of these therapies, although this does not prevent physicians to use all sorts of off-label
318 therapies despite the risk of serious adverse events.²⁶ Therapies to curb uncontrolled
319 cytokine release have been proposed and are being widely used. Randomized controlled
320 trials with host-directed therapies are currently under way and results will be available
321 within the next months.^{17,18} Meanwhile, data from prospective studies can help to improve
322 COVID-19 patient management. In our study, the 7-day mortality was 26.8%, slightly
323 higher than a recent experience with remdesivir and similar to the mortality of 22.1%
324 reported in another study with lopinavir/ritonavir.^{27,28} However, the patients in our
325 prospective cohort had more coexisting conditions, including potential mortality risk
326 factors such as hypertension, other cardiovascular and metabolic diseases, chronic kidney
327 disease and cancer.

328 The understanding of mortality risk factors in patients with COVID-19 is an evolving
329 matter. Age, specific coexisting conditions and laboratory parameters may help identify
330 patients with poor outcome.²⁹ As expressed before, in our cohort of patients treated with
331 tocilizumab, hypertension, history of cardiac failure and chronic kidney disease were
332 associated with higher mortality in the univariate analysis. Antihypertensive agents, such as

333 angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers
334 (ARB), have been suggested to be associated with the increased mortality observed in this
335 subset of patients. Angiotensin converting enzyme 2 plays an important role in SARS-CoV-
336 2 viral entry as co-receptor.³⁰ Hypothesis outline that the interactions between these drugs
337 and co-receptors may increase viral spreading in the lung and increase risk of death.
338 However, the evidence is limited and no specific recommendations could be drawn from
339 current evidence, especially when ACEI and ARB have shown to reduce mortality in this at
340 risk population.³¹ The Vall d'Hebron COVID-19 Prospective Cohort Study has among its
341 main objectives to analyse the role of these and other drugs used to treat chronic conditions
342 in the prognosis of patients with COVID-19.

343 Host-directed therapies aiming at blocking an unrestrained immune response and an
344 excessive inflammation have been proposed as potential therapies to prevent acute lung
345 injury and subsequent ARDS. SARS-CoV-2 infection severity has been associated with an
346 increase in IL-6 and D dimer levels, and the cytokine profile resembles that of other
347 conditions in which host-directed therapies have been successfully used.^{13,29,32} Timely use
348 of host-directed therapies may curb uncontrolled cytokine release and prevent damage
349 inflicted by hyperinflammation. Tocilizumab has shown to be safe in two small Chinese
350 cohort studies of patients with COVID-19.^{9,16} Efficacy of tocilizumab, measured as hospital
351 discharge, was 90.5% (19 out of 21 patients) in patients with COVID-19 needing oxygen
352 supplementation and having elevated IL-6 in one study⁹; while the other study showed 3
353 deaths, 10 clinical stabilizations and 2 clinical aggravations out of 15 patients.¹⁶ Other
354 laboratory and radiologic findings also improved in a short period of time. However,
355 standard of care in the studies was different limiting the possibility of direct comparisons.
356 As in other infections and inflammation-driven diseases, timely initiation of precise therapy

357 is the mainstay of patient management and directly affects mortality and morbidity. Our
358 study showed that patients receiving prompt treatment with tocilizumab before lung injury
359 is established have less 7-day mortality, a benefit that may be sustained in the long-term.³³
360 The safety profile of tocilizumab has been extensively studied in clinical trials with patients
361 suffering autoimmune diseases. The most common adverse events of intravenous
362 tocilizumab in a pooled analysis of 3 clinical trials were upper respiratory infections,
363 nasopharyngitis, headache, hypertension and increase in liver enzymes. Serious adverse
364 events occurred in 12% of the patients, infectious diseases being the most common.³⁴ In our
365 study we did not report any serious adverse events, although the symptoms of systemic
366 viral infections may mimic any adverse event and make its identification difficult.
367 Tocilizumab-related bacterial infections were not reported in our study. Two factors may
368 have contributed to this: first, many patients were under antibiotic treatment, and second,
369 the short follow up period precludes us from any further analysis. Nevertheless, the low
370 cumulative dose administered in this subset of patients may diminish the likelihood of
371 infectious adverse events.
372 In a time of scarce medical resources, including limited stock of host-directed therapies,
373 hard medical decisions have to be done by front-line physicians. Allocation of therapies to
374 patients with the highest chances of a favourable outcome should be encouraged,
375 maximizing the benefit of the intervention.³⁵ Evidence-based decision-making and benefit-
376 maximizing allocation of the available resources should be promoted. In this regard our
377 study can help physicians to better allocate host-directed therapy in patients with COVID-
378 19 prioritizing moderate-to-severe ill patients over critically ill patients.
379 This preliminary exploratory study has several limitations. First, there is no control group
380 and the minimum follow up period was 7 days. Therefore, at this point it is not possible to

381 evaluate the differences between patients receiving tocilizumab or not and, consequently, it
382 is not possible to evaluate solidly what is the overall benefit of administering this drug.
383 However, the urgency of obtaining data on new therapies justifies the early communication
384 of these results. Second, ICU admission is not a very robust endpoint since it depends on
385 the attitudes of the treating physicians as well as the availability of beds at times of resource
386 scarcity and overwhelming demand. For this reason, mortality was selected as the main
387 outcome in our study. Besides, the subsequent analysis of all patients included in the Vall
388 d'Hebron COVID-19 Prospective Cohort Study may solve this limitation and inform results
389 with a longer follow up period. Finally, our data is limited to a single centre. While our
390 results may not be extrapolated to other populations or other standards of care, the
391 management of patients was homogeneous avoiding the centre effect of multicentric
392 studies. Multivariate analysis is limited by sample size.

393 **CONCLUSION**

394 In summary, we found a mortality rate of 26.8% in this subset of patients with COVID-19
395 receiving tocilizumab for the treatment of inflammatory-related lung injury. Time from
396 lung injury onset to tocilizumab administration may be critical to patient recovery. Our
397 results may help front-line physician to make evidence-based decisions in times of scarce
398 resources and operationalized fair and transparent allocation procedures, maximizing the
399 benefit of the intervention. Future and current host-directed clinical trials for patients with
400 COVID-19 should consider our preliminary data in their design. All our patients were
401 treated with a combination of antiviral drugs whose efficacy is yet to be demonstrated.
402 Host-directed therapies in the absence of antiviral drugs needs further investigation.

403 **ACKNOWLEDGEMENT**

404 None

405 **CONFLICTS OF INTEREST**

406 None

407

408 **CONTRIBUTION STATEMENT:**

- 409 • Conceived the idea: ASM, JEP, JSN, NFH, BA
- 410 • Reviewed medical chart and collected data. ASM, JSM, JEP, NFH, FS, XD, MM, AA,
411 SEE, ASG, AMP, PBM, SA, JS, AGdC.
- 412 • Supervised the findings: ASM, JEP, JSN, NFH, BA
- 413 • Performed statistical analysis: ASM, JEP, NFH, SPH
- 414 • Wrote the manuscript with inputs from all authors: ASM, JEP, NFH
- 415 • Supervised the project: ASM, JS, BA
- 416 • Interpretation of the results: ASM, JSM, JEP, NFH, FS, XD, MM, AA, SEE, ASG, AMP,
417 PBM, SA, JS, AGdC.
- 418 • Critically reviewed the manuscript: ASM, JSM, JEP, NFH, FS, XD, MM, AA, SEE, ASG,
419 AMP, PBM, SA, JS, AGdC.
- 420

421 **REFERENCES**

- 422 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
423 coronavirus in Wuhan, China. *Lancet Lond Engl* 2020;395(10223):497–506.
- 424 2. Novel Coronavirus (2019-nCoV) situation reports [Internet]. [cited 2020 Apr
425 1]; Available from: [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
426 [2019/situation-reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
- 427 3. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The
428 epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases
429 (COVID-19) in China]. *Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua*
430 *Liuxingbingxue Zazhi* 2020;41(2):145–51.
- 431 4. Hauser A, Counotte MJ, Margossian CC, et al. Estimation of SARS-CoV-2 mortality
432 during the early stages of an epidemic: a modelling study in Hubei, China and
433 northern Italy. *medRxiv* 2020;2020.03.04.20031104.
- 434 5. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus
435 infections. *Expert Rev Anti Infect Ther* 2006;4(2):291–302.
- 436 6. Al-Tawfiq JA, Memish ZA. Update on therapeutic options for Middle East
437 Respiratory Syndrome Coronavirus (MERS-CoV). *Expert Rev Anti Infect Ther*
438 2017;15(3):269–75.
- 439 7. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a
440 treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J*
441 *Antimicrob Agents* 2020;105949.
- 442 8. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with
443 COVID-19: results of a randomized clinical trial. *medRxiv*
444 2020;2020.03.22.20040758.
- 445 9. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with
446 tocilizumab. Available from: chinaXiv:202003.00026v1 (2020).
447 www.chinaxiv.org/abs/202003.00026
- 448 10. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated
449 with decreased mortality in severe coronavirus disease 2019 patients with
450 coagulopathy. *J Thromb Haemost JTH* 2020;
- 451 11. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-
452 nCoV acute respiratory disease. *Lancet Lond Engl* 2020;395(10223):e30–1.
- 453 12. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19:
454 consider cytokine storm syndromes and immunosuppression. *The Lancet*
455 2020;395(10229):1033–4.

- 456 13. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-
457 nCoV: host-directed therapies should be an option. *Lancet Lond Engl*
458 2020;395(10224):e35–6.
- 459 14. Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of
460 rheumatoid arthritis: an evidence-based review and patient selection. *Drug Des Devel*
461 *Ther* 2019;13:57–70.
- 462 15. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells:
463 recognition and management. *Blood* 2016;127(26):3321–30.
- 464 16. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a
465 single center experience. *J Med Virol* 2020;
- 466 17. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With
467 COVID-19 - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Apr
468 11]; Available from: <https://clinicaltrials.gov/ct2/show/NCT04315298>
- 469 18. Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia - Full
470 Text View - ClinicalTrials.gov [Internet]. [cited 2020 Apr 11]; Available from:
471 <https://clinicaltrials.gov/ct2/show/NCT04331665>
- 472 19. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired
473 pneumonia severity on presentation to hospital: an international derivation and
474 validation study. *Thorax* 2003;58(5):377–82.
- 475 20. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis.
476 *JAMA* 2016;315(8):762–74.
- 477 21. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-
478 nCoV) in suspected human cases. *WHO - Interim Guid* 2020;2019(January):1–7.
- 479 22. Moës E, Vijgen L, Keyaerts E, et al. A novel pancoronavirus RT-PCR assay: frequent
480 detection of human coronavirus NL63 in children hospitalized with respiratory tract
481 infections in Belgium. *BMC Infect Dis* 2005;5:6.
- 482 23. Woo PCY, Lau SKP, Lam CSF, et al. Discovery of a novel bottlenose dolphin
483 coronavirus reveals a distinct species of marine mammal coronavirus in
484 *Gammacoronavirus*. *J Virol* 2014;88(2):1318–31.
- 485 24. Force TADT. Acute Respiratory Distress Syndrome: The Berlin Definition. *JAMA*
486 2012;307(23):2526–33.
- 487 25. Festic E, Bansal V, Kor DJ, Gajic O. SpO₂/FiO₂ Ratio on Hospital Admission Is an
488 Indicator of Early Acute Respiratory Distress Syndrome Development Among
489 Patients at Risk. *J Intensive Care Med* 2013;30(4):209–16.

- 490 26. Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and
491 Randomized Clinical Trials During Pandemics. JAMA 2020;
- 492 27. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients
493 with Severe Covid-19. N Engl J Med 2020;
- 494 28. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized
495 with Severe Covid-19. N Engl J Med 2020;
- 496 29. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
497 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
498 Lond Engl 2020;395(10229):1054–62.
- 499 30. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new
500 coronavirus of probable bat origin. Nature 2020;579(7798):270–3.
- 501 31. Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and
502 Angiotensin Receptor Blockers: What Is the Evidence? JAMA 2020;
- 503 32. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and
504 management of cytokine release syndrome. Blood 2014;124(2):188–95.
- 505 33. Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS. The long-term impact of severe
506 acute respiratory syndrome on pulmonary function, exercise capacity and health
507 status. Respirol Carlton Vic 2010;15(3):543–50.
- 508 34. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term
509 safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in
510 monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of
511 safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68(10):1580–4.
- 512 35. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources
513 in the Time of Covid-19. N Engl J Med 2020;
- 514

515 **FIGURES**

516 Figure 1. 7-day mortality curves according to the moment patients received tocilizumab:
517 before or after developing ARDS. ARDS: acute respiratory distress syndrome.

518 Figure 2. 7-day mortality curves according to the moment patients received tocilizumab:
519 before or after developing respiratory insufficiency.

520 Figure 3. Outcome according to nearest SpO₂/FiO₂ ratio to tocilizumab administration

521 Figure 4. Nearest SpO₂/FiO₂ ratio to tocilizumab administration distribution according to
522 7-days outcome

523

524 **TABLES**

525 **Table 1.** Demographic and clinical characteristics of the patients at baseline*

Characteristics	Patients (n=82)
Age, mean - yr	59.1 ±19.8
Sex – no (%)	
Male	52 (63.4%)
Female	30 (36.6%)
Origin	
Spain	63 (77.8%)
Latin America	13 (16.1%)
East Europe	3 (3.7%)
North Africa (Magreb)	2 (2.4%)
Coexisting condition – no (%)	
Active tobacco smoker	5 (6.1%)
Former tobacco smoker	28 (34.2%)
Never smoke	49 (59.8%)
Active daily alcohol consumption	1 (1.2%)
Former daily alcohol consumption	2 (2.4%)
Never drink daily	79 (96.3%)
Cognitive imparment	1 (1.2%)
Diabetes Mellitus	16 (19.5%)
Immunosuppression	10 (12.2%)
Solid organ transplant	5 (6.1%)
Drug induced immunosuppression	3 (3.7%)
Bone marrow transplant	1 (1.2%)
Other	1 (1.2%)
Former cancer (includes any solid cancer)	9 (11.1%)
Active cancer (includes any solid cancer)	2 (2.4%)
Former haematological condition (includes leukemia and lymphoma)	3 (3.7%)
Active haematological condition (includes leukemia and lymphoma)	2 (2.4%)
Hypertension	32 (39%)
Hystory of cardiac failure	5 (6.1%)
Atrial fibrillation	10 (12.2%)
Lung diseases –	19 (23.5%)
Chronic obstructive pulmonary disease	6 (7.3%)
Obstructive sleep apnea syndrome	3 (3.7%)
Insterstitial lung disease	2 (2.4%)
Asthma	2 (2.4%)
Bronchiectasis	2 (2.4%)
Lung restritive disease	2 (2.4%)
Lung transplant	2 (2.4%)
Pulmonary hypertension	1 (2.4%)

Controlled pulmonary tuberculosis	1 (2.4%)
Chronic kidney disease	11 (13.6%)
GFR>50	3 (27.3%)
GFR 30-50	4 (36.4%)
GFR<30	4 (36.4%)
Renal supportive therapy (hemodialysis)	2 (18.2%)
Cirrhosis	1 (1.2%)
Central nervous system disease	2 (2.4%)
Obesity	17 (20.7%)
Mean duration of symptom before admission (days)	6.7 ±4.4
Mean days from symptom onset to dyspnea	1.14 ±3.6
Mean duration of dyspnea before admission	3.48±3.2
Symptoms	
Fever	75 (91.5%)
Cough	71 (86.6%)
Shortness of breath	54 (65.9%)
Sore throat	1 (1.2%)
Sputum production	8 (9.8%)
Rhinorrhea	1 (1.2%)
Headache	1 (1.2%)
Lost of weight	4 (4.9%)
Malaise	46 (56.1%)
Hemoptysis	5 (6.1%)
Chest pain	21 (25.6%)
Anosmia	4 (4.9%)
Cacosmia	3 (3.7%)
Muscle and joint pain	14 (17.1%)
Nauseas	3 (3.7%)
Vomits	36 (43.9%)
Diarrhea	8 (9.8%)
Profuse sweating	2 (2.4%)
Barthel scale 100 previous to symptoms onset †	77 (93.9%)
ECOG ≤ 1 previous to symptoms onset ‡	78 (95.1%)
Median (IQR), age-adjusted Charlson index at baseline - points §	3 (1-4)
Median (IQR), SOFA index at admission - points ¶	1 (0-3)
CURB-65 ≥ 3 §	18 (22%)

526 *Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may not be
527 100 because of rounding.

528 †Barthel index total scores range from 0 to 100, with higher scores indicating a better
529 performance of 10 basic daily self-care activities. ‡ The Eastern Cooperative Oncology Group (ECOG)
530 performance scale range from 0 (fully active) to 4 (completely disabled). § The Charlson risk index

531 score ranges from 0 to 37 with higher scores indicating a higher risk of death. ¶ Sequential Organ
532 Failure Assessment (SOFA) score ranges from 0 to 24 with higher ranges indicating a higher risk or
533 morbidity; individuals with a score of 15 or more have a mortality rate of 90%. Its calculation is
534 missing in two patients. § Community acquired pneumonia severity index assessing Confusion,
535 Urea, Respiratory rate, Blood pressure and age over 65 years (CURB-65) ranges from 0 to 5
536 depending on the number of risk factors present in the same patient.

537 GFR: glomerular filtration rate.

538 – One patient had interstitial lung disease and pulmonary hypertension and another patient had
539 obstructive sleep apnea syndrome and lung restrictive disease.

Table 2. Status on admission and follow up*

	Admission (n=82) †	48 hours (n=79) †	7 days (n=51) †
Vital signs on admission – no. (%)			
Systolic blood pressure, mean - mmHg	128.3±18.3	120.8 ±17.7	125.0 ±19.4
Diastolic blood pressure, mean - mmHg	73 ±12.2	71.3 ±9.3	72.3 ±10.7
Temperature, mean - °C	37.7 ±0.9	36.8 ±0.8	36.4 ±0.7
Heart rate, mean - rates per minute	94.3 ±17.8	79.7 ±12.0	79.0 ±14.2
Respiratory rate, mean - breaths per minute	23.9 ±6.3	21.5 ±6.0	22.5 ±11.5
Temperature > 37.8°C	34 (42.5%)	9 (12.1%)	1 (1.6%)
Heart rate > 100 beats per minute	28 (65.4%)	3 (3.8%)	7 (11.5%)
Respiratory rate > 20 breaths per minute	39 (58.2%)	24 (40%)	23 (46.9%)
Oxygen saturation, mean	94.0 ±4.4	94.1 ±3.9	93.6 ±6.9
Physical examination – no. (%)			
Glasgow coma scale of 15	82 (100%)		
Abnormal lung sounds			
Crackles	62 (75.6%)	54 (67.5%)	39 (58.2%)
Hypophonesis	9 (11%)	7 (8.6%)	5 (7.5%)
Wheezing	5 (6.1%)	2 (2.5%)	0 (0%)
Rhonchus	5 (6.1%)	2 (2.5%)	2 (3%)
Imaging characteristics – no. (%)			
Type of chest radiography alteration†			
Unilateral or bilateral infiltrate	20 (24.4%)	17 (21.3%)	21 (31.3%)
Interstitial pattern	10 (12.2%)	4 (5%)	7 (10.5%)
Pleural effusion	2 (2.4%)	1 (1.3%)	0 (0%)
Atelectasis	1 (1.2%)	1 (1.3%)	0 (0%)
Extension of abnormality in chest radiography PA projection			
<33%	32 (39.0%)	4 (5%)	4 (5.97%)
33-66%	38 (46.3%)	6 (7.5%)	9 (13.43%)
>66%	10 (12.2%)	9 (11.25%)	13 (19.45%)

*Plus-minus values are means (\pm SD). Rounding has been applied to percentages. Total may not be 100 because of rounding.

†Total number of patients varies among variables and follow up as mortality increases.

‡Some patients have more than one radiologic abnormality.

PA, posteroanterior.

Table 3. Laboratory data at admission and follow up*

Laboratory data – no. (%)	Admission (n=82) †	48 hours (n=79) †	7 days (n=51) †
Red cell count			
Haemoglobin, mean – gr/dl	13.3 ±1.6	12.7 ±1.6	12.5 ±1.5
≥ 10 gr/dl – no. (%)	78 (96.3%)	41 (93.2%)	43 (95.6%)
White cell count			
Mean (SD) – per mm ³	9.2 ±10.4	6.7 ±3.8	7.1 ±3.5
Distribution – no. (%)			
≥ 10000/mm ³	17 (21.3%)	5 (11.4%)	9 (20%)
≤4000/mm ³	7 (8.8%)	10 (22.7%)	9 (20%)
Lymphocyte count			
Median (IQR) – per mm ³	868.9 (593.7-1205.5)	710.5 (491.5-1154.9)	1112.0 (575.1-1519.6)
Distribution – no. (%)			
≥ 1000/mm ³ – no. (%)	34 (42.5%)	15 (34.1%)	23 (51.1%)
Platelet count, mean – per mm ³	199 ±87.2	235.7 ±139.4	282.3 ±141.6
Prothrombin time, mean - %	77.9 ±23.8		
Activated partial thromboplastin time, mean - seconds	24.6 ±9.8		
Fibrinogen, mean – gr/dl	5.6 ±1.0		
D dimer, median (IQR) - ng/ml	295 (201-437)	565 (303-772)	738 (273.5-2963)
Glucose, mean - mg/dl	120.2 ±36.7		
Urea, median (IQR) – mg/dl	43 (38-72)		
Serum creatinine, mean - mg/dl	1.7 ±6.1	2.1 ±7.1	0.9 ±0.6
Glomerular filtrate, mean – CKD-EPI	73.5 ±23.8	73.1 ±26.5	77.25 ±19.9
Sodium, mean – mmol/L	136.0 ±3.7		
Potassium, mean – mmol/L	3.9 ±0.7		
Calcium, mean – mg/dl	8.9 ±0.5		
Total bilirubin, mean – mg/dl	0.7 ±0.5		
Aspartate aminotransferase, mean - U/litre	53.1 ±34.3	53.7 ±35.4	71.4 ±46.2
Aspartate aminotransferase > 40 U/litre	42 (53.9%)	25 (61%)	30 (66.7%)

Alanine aminotransferase, mean - U/litre	41.68 (34.4)	43.4 (31.7)	77.3 (71)
Alanine aminotransferase > 40 U/litre	28 (35.4%)	16 (39.0%)	30 (66.7%)
Alkaline phosphatase, mean - U/litre	69.80 ±21.7		
Gamma-glutamyl transferase, mean – U/litre	93 ±58.0		
LDH, mean - UI/L	446.61 ±79.5		
CRP, mean - mg/dl	17.98 ±11.7	17.5 ±10.0	6.3 ±9.2
Ferritin, mean - ng/ml	885.69 ±500.5	1505.4 ±1194.6	1241.6 ±789.2
Proteins, mean - gr/dl	7.38 ±0.7		
Albumin, mean - gr/dl	3.30 ±0.3		
IL-6, median (IQR) - pg/ml	74.8 (49.4-120.0)	184.1 (75.3-592.6)	501.2 (103.7-2361.0)
Infection analysis			
Positive blood cultures	1 (1.3%)	0 (0%)	1 (10%)
Positive sputum cultures	3 (4.3%)	0 (0%)	2 (22.2%)
Positive pneumococcal urinary antigen	2 (2.5%)	0 (0%)	0 (0%)

*Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may not be 100 because of rounding.

†Total number of patients varies among variables and follow up as mortality increases.

Table 4. Oxygen supplementation and supportive ventilation on admission and follow up*

	Admission (n=82) †	48 hours (n=79) †	7 days (n=51) †
Respiratory frequency, mean – rate per minute	23.9 ±6.3	21.6 ±6	22.5 ±11.5
Oxygen saturation, mean	94 ±4.4	94 ±3.9	93.6 ±6.9
SpO ₂ /FiO ₂ ratio, median (IQR)	428 (316.1-454.8)	271.4 (158.3-361.5)	230.2 (118.8-346.4)
Oxygen supplementation and supportive ventilation – no. (%)			
Nasal cannula	2 (5.9%)	6 (9%)	4 (7.0%)
Face masks	22 (64.7%)	33 (49.3%)	16 (28.1%)
High oxygen supplementation device	9 (26.5%)	11 (16.4%)	6 (10.5%)
High flow nasal cannulas	0 (0%)	10 (14.9%)	16 (28.1%)
Non-invasive mechanical ventilation	0 (0%)	2 (3%)	3 (5.3%)
Invasive mechanical ventilation	1 (2.9%)	5 (7.5%)	12 (21.1%)

*Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may not be 100 because of rounding.

†Total number of patients varies among variables and follow up as mortality increases.

SpO₂/FiO₂ ratio: arterial oxygen saturation measured by pulse oximetry to fraction of inspired oxygen

Table 5. Secondary outcomes at 7-day follow up from tocilizumab administration.

Outcome – no. (%)	Patients
Vasopressor therapy	15 (19.7%)
Acute respiratory distress syndrome	45 (64.3%)
Respiratory failure	62 (84.9%)
Cardiac failure	1 (1.5%)
Septic shock	1 (1.6%)
Acute kidney injury	9 (13.9%)
Concomitant infection	1 (1.5%)

Table 6. Main outcome at 7-day follow up from tocilizumab administration.

Main outcomes – no. %	Patients
Discharge	34 (41.5%)
In-patient in conventional ward	9 (11.0%)
Intensive care unit	14 (17.1%)
Death	22 (26.8%)
Transferred	3 (3.7%)

Table 7. Comparison of risk factors by in-hospital mortality.

Characteristics	Alive (n=60)	Dead (n=22)	P-value
Demographics			
Age, mean (SD) - yr	53.3 (19.9)	75.2 (6.2)	<0.001
Sex – no (%)	36 (60.0)	16 (72.7)	0.289
Coexisting condition – no (%)			
Tobacco use			0.397
Active tobacco smoker	5 (8.3)	-	
Former tobacco smoker	19 (31.7)	9 (40.9)	
Never smoke	36 (60.0)	13 (59.1)	
Alcohol use			0.070
Active daily alcohol consumption	1 (1.7)	-	
Former daily alcohol consumption	-	2 (9.1)	
Never drink daily	59 (98.3)	20 (90.9)	
Barthel index at admission, median (IQR)	100 (100-100)	100 (100-100)	0.371
Dementia	1 (1.7)	-	1
Diabetes Mellitus	12 (20.0)	4 (18.2)	1
Immunosuppression	5 (8.3)	5 (22.7)	0.123
Solid tumor	3 (5.1)	6 (27.3)	0.012
Leukemia/Lymphoma	2 (3.3)	1 (4.6)	1
Hypertension	17 (28.3)	15 (68.2)	0.001
Chronic heart failure	1 (1.7)	4 (18.2)	0.017
Chronic lung disease	11 (18.6)	8 (36.4)	0.094
Chronic renal failure	4 (6.7)	7 (33.3)	0.005
Liver cirrhosis	1 (1.7)	-	1
Central nervous system disease	1 (1.7)	1 (4.6)	0.467
Obesity	14 (23.3)	3 (13.6)	0.539
Median (IQR), age-adjusted Charlson index at baseline - points	2 (1 – 3)	5 (3 – 6)	<0.001
Oxygenation previous to tocilizumab administration			

Oxygen saturation (pulse oximeter) at baseline, median (IQR)	95 (94 - 97.5)	93 (89 - 97)	0.061
FiO2 at baseline, median (IQR)	0.21 (0.21 - 0.28)	0.26 (0.21 - 0.50)	0.130
SpO2/FiO2 ratio at baseline, median (IQR)	440 (343-455)	393 (180-452)	0.134
High oxygen supplementation or ventilation at baseline* - no. (%)	-	1 (4.6%)	0.268
Oxygen saturation (pulse oximeter) at tocilizumab administration, median (IQR)	95 (93-97)	92 (89-94)	0.006
FiO2 previous to tocilizumab administration, median (IQR)	0.27 (0.21-0.40)	0.35 (0.21-1)	0.131
SpO2/FiO2 ratio previous to tocilizumab administration, median (IQR)	354 (228-438)	263 (95-423.8)	0.072
High oxygen supplementation or ventilation previous to tocilizumab administration*	3 (5%)	4 (18%)	0.79
Days from initial symptoms to tocilizumab administration, median (IQR)	9 (7 - 11)	7 (5 - 15)	0.372
Days from admission to tocilizumab administration, median (IQR)	2 (1 - 3)	3 (1 - 4)	0.064
Days from respiratory insufficiency to tocilizumab administration, median (IQR)	0 (0 - 1)	1 (0 - 2)	0.055
Days from ARDS to tocilizumab administration, median (IQR)	0 (-1 - 0)	0 (0 - 1)	0.132

*Plus-minus values are means (\pm SD). Rounding has been applied to percentages. Total may not be 100 because of rounding.

†Includes high flow oxygen delivery systems, high flow nasal cannula, non-invasive mechanical ventilation or invasive ventilation

ARDS: acute respiratory distress syndrome.